quarter. Thanks, Dan. joining call for I'll review our the turning for Jason the provide thank Good to and to update the three XXXX. each financial corporate a provide of product afternoon, third quarter for of candidates before you for updates results our our us stage everyone, clinical call for over
The skin the the a endpoints XX% trial for currently survival response sites being four or for the outcomes life for endpoint planned the lymphoma which and progression of SOLAR in to monitor secondary in cutaneous or over XX% we as is including greater of trial approximately objective plan body SOLAR of months. a lymph additional the is evidence clinical the for SOLAR no currently patient-reported We've Progression-free disease with Starting is rate clinical to indications blood, opened consecutive quality the severity CTCL. maintained secondary at disease defined entire trial. for least in clinical with X of use a patient's primary cobomarsen, nodes evaluated three improvements. or trials Phase improvement the multiple viscera, endpoint, as T-cell
discussions we the endpoint CTCL in the from FDA, believe allow our States. accelerated cobomarsen with could on of SOLAR United to Based trial the achieving apply primary that the us approval for in
from XXXX. Today, our we on XXXX this trial updated report when the half expect to from data primary we of half guidance second to first of endpoint clinical the
was enrollment. to enrollment to our in of based today time resulting slower-than-anticipated Our our number on activate support decision longer-than-anticipated guidance patient adjust the to patient sites projections, previous
are While as States additional United guarantees, enrollment no there to Europe, patient believe increase the become proportionately. expect active we and that sites we in
as a study enrollment one And an with supported of an under trial. is purchase Leukemia common result, its has In help Society additional SOLAR reminder, provide the $X.X XXXX, SOLAR trial and stock a achieved the the by our miRagen a through agreed support the one collaboration of purchased LLS. or of common million Lymphoma As up October the affiliates part affiliate $X in million LLS the milestones to LLS of this of to stock. agreement. to through
levels, correlated the cobomarsen. in in three evaluated where being also appears microRNA-XXX indications is process expansion increase X the disease with Cobomarsen a of an target in trial be Phase potential clinical to
patients be patients treatment stabilization a observed with is durability for in of of meaningful option T-cell focus on forms cobomarsen with The date initial we've subtypes leukemia/lymphoma. Our treating belief of to potential ATLL that aggressive support these disease the ATLL. adult and released data our showed with patients may
have further clinical believe we supports in utility other other CTCL, tumor treating elevated levels. elevated cobomarsen than a may microRNA-XXX microRNA-XXX these type with malignancies that in observations addition, the In hypothesis
to Turning to in for fibrosis to therapies need. where program fibrosis deliver microRNA-XX for therapies has the pathologic potential our deliver other promising in mimics, distinct opportunity believe an indications miRagen attractive has patients we been remlarsen and implicated, providing
was of liver action then skin administration, other as and development mechanism with remlarsen strategy requiring indications diseases other mimics, and by lung initiate remlarsen to demonstrating the microRNA-XX including Our potentially with potential into in such expand and systemic fibrosis.
prevention safety, previously conducting formation subjects of keloid disclosed, currently trial scarring. and the in history we clinical the of are a assessing of keloid of tolerability As a in a pathological with potential X Phase or remlarsen activity scars, form we've reduction
of this data clinical to from end X expect report the trial year. by We this Phase interim
ocular also hazing observed the that and this reduced expression accelerated We cornea we effects topically Earlier the retina. multiple antifibrotic the remlarsen healing year, studies, fibrosis corneal and released remlarsen injury, preclinical the corneal regimes and of reduce appeared data of administered of exploring associated to in from scarring.
concomitant In in reductions administered addition, of biomarkers observed showed we that good the remlarsen multiple with across biodistribution retina fibrosis. intravitreally
injury. treatments scarring a fibrosis blindness hazing the for and approved the data no our cause X be clinical remlarsen of we as This ophthalmic of leading and in which preclinical remains treating data cornea following this safety prevention the indications medical on corneal Based from exist. worldwide, need including scarring in resulting trial, may of believe Phase pharmacologic an is significant a effective infection or
could are indications lung idiopathic the we've as developing I or or that and liver, utility new NASH. have have steatohepatitis IPF implicated mimics treatment fibroses earlier, where we believe in pulmonary fibrosis discovered systemic such microRNA-XX nonalcoholic and for and been As in mentioned
series product that these observations in reduce IPF our matrix second-generation studies. May, In the mimic deposition effectively, extracellular previous in IPF, demonstrating believe of microRNA-XX with the pathologic We that of data lung. fibrosis coupled data support reported we efficiently of a preclinical new for with appeared to in in humans role administration systemic candidate MRG-XXX, microRNA-XX
development date will financial product Future candidates that potential candidates. require the believe resources generated of and to we've these program data our supports multiple additional or We product the evaluating collaborations. development continued fibrosis
data data demonstrated by month, of increased from Turning one trials angiogenesis of MRG-XXX to histological MRG-XXX. X as neoangiogenesis. these clinical may humans was clinical patients. failure increase the In that expected MRG-XXX. to in future clinical heart other biomarkers trials Phase such provide as trials is perfusion announced two and treatment observed these in support translatable markers of conditions clinically the of generated lacerations high-risk and for studies of in administration trials, clinical Last we – The in complicated to
that was safe the MRG-XXX Phase well X trials, clinical generally both is to development. tolerated, program advance we ready and In believe clinical to and
new may future. this have not we development a While development seek product for plans for MRG-XXX, in we the collaboration announced future candidate
microRNA-targeted differentiates candidate our the developed has third tolerated of proof As and team humans. and well the data and product been preliminary generally that mechanism has technology We demonstrates a represents product miRagen's this capability of our reminder, believe candidates. to in safe team develop MRG-XXX with microRNA-targeting
Financial turn call the earlier our will Jason to Chief Officer, that, With results to now financial we reported over the Leverone, I review today. Jason?
